Five pros including specialty API expertise and CDMO growth, and four cons including USFDA risk and customer concentration, of Neuland Laboratories share.

Alembic Q1 FY27 results: Revenue Rs 48 Cr, PAT Rs 15 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here.

KP Energy Q1 FY27 results: Revenue Rs 519 Cr, PAT Rs 26 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here.

Tribhovandas Bhimji Zaveri Q1 FY27 results: Revenue Rs 840 Cr, PAT Rs 33 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here.

Vikran Engineering Q1 FY27 results: Revenue Rs 141 Cr, PAT Rs 3 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here.

Arkade Developers Q1 FY27 results: Revenue Rs 146 Cr, PAT Rs 19 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here.

Five pros including strong North India diagnostic brand and hub-and-spoke model, and four cons including competition from Metropolis and low-cost rivals, of Dr Lal PathLabs share.

Simplex Infrastructure Q1 FY27 results: Revenue Rs 290 Cr, PAT Rs 10 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here.

Prakash Industries Q1 FY27 results: Revenue Rs 1,032 Cr, PAT Rs 71 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here.

Landmark Cars Q1 FY27 results: Revenue Rs 1,302 Cr, PAT Rs 14 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here.